Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: There are only few case reports about surgery in patients affected by gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients previously underwent peptide receptor radionuclide therapy (PRRT).
Conference: 10th Annual ENETSConcerence (2013)
Presenting Author: Bertani E
Authors: Bertani E, Fazio N, Cossu M, Chiappa A, Corbellini C,
Keywords: gastroenteropancreatic neuroendocrine tumors, surgery, peptide receptor radionuclide therapy, multidisciplinary approach, long-term survival.,
Introduction: Few studies report the association of neurological syndromes with a carcinoid, the majority being small-cell lung cancer.
Conference: 9th Annual ENETSConcerence (2012)
Presenting Author:
Authors: Brizzi M, Ferrero A, Ottone A, Bellini E, Bitossi R,
Keywords: paraneoplastic syndrome,
#431 Everolimus Controlled Resistant Hypoglycemia in Malignant Insulinoma
Introduction: A pancreatic neuroendocrine carcinoma with liver metastases was diagnosed on July 2006 in a 65-year-old man. He was treated with octreotide LAR 30 mg for three years. At liver progression he was enrolled in a multicenter Italian trial titled “XELBEVOCT” with Bevacizumab + Metronomic Capecitabine + Octreotide LAR 30 mg. After seven months, the patient exhibited severe hypoglycemic syndrome with HGT serum levels<30 mg/dl, insulin 150 microUI/ml, and C-peptide at upper normal limits. Endocrinologist prescribed prednisone, diazoxide and recombinant glucagon for hypoglicemic crisis, with little benefit. In March 2010, the patient was given radio-labelled Lu-177-OCTREOTATE treatment. After three cycles, hypoglicemic symptoms were still uncontrolled. CT scan showed stable disease.
Conference: 9th Annual ENETSConcerence (2012)
Presenting Author:
Authors: Ferrero A, Bellini E, Brizzi M, Pia A, Ottone A,
Keywords: malignant insulinoma, everolimus, resistant hypoglycemia,